Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 203


Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease.

Bangalore S, Fayyad R, Laskey R, Demicco DA, Deedwania P, Kostis JB, Messerli FH; Treating to New Targets Steering Committee and Investigators.

Am J Med. 2014 Jan;127(1):71-81.e1. doi: 10.1016/j.amjmed.2013.07.038. Epub 2013 Nov 7.


A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW; INVEST Investigators.

JAMA. 2003 Dec 3;290(21):2805-16.


Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.

Bakris GL, Cooper-Dehoff RM, Zhou Q, Kupfer S, Champion A, Pepine CJ; INVEST Investigators.

Am J Cardiovasc Drugs. 2007;7 Suppl 1:25-9.


Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.

Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators.

JAMA. 2004 Nov 10;292(18):2217-25.


Office management of hypertension in older persons.

Aronow WS.

Am J Med. 2011 Jun;124(6):498-500. doi: 10.1016/j.amjmed.2010.06.029.


Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ; CONVINCE Research Group.

JAMA. 2003 Apr 23-30;289(16):2073-82.


Prevalence and predictors of resistant hypertension in a primary care setting: a cross-sectional study.

Chia YC, Ching SM.

BMC Fam Pract. 2014 Jul 5;15:131. doi: 10.1186/1471-2296-15-131.


Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.

Bangalore S, Fayyad R, Laskey R, DeMicco D, Deedwania P, Kostis JB, Messerli FH; Treating to New Targets Steering Committee and Investigators.

Eur Heart J. 2014 Jul 14;35(27):1801-8. doi: 10.1093/eurheartj/eht315. Epub 2013 Aug 29.


Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.

Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS.

JAMA. 2003 May 21;289(19):2534-44.


Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST).

Winchester DE, Cooper-Dehoff RM, Gong Y, Handberg EM, Pepine CJ; INVEST Investigators.

Clin Cardiol. 2013 Aug;36(8):442-7. doi: 10.1002/clc.22145. Epub 2013 May 29.


Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study.

Smith SM, Huo T, Delia Johnson B, Bittner V, Kelsey SF, Vido Thompson D, Noel Bairey Merz C, Pepine CJ, Cooper-Dehoff RM.

J Am Heart Assoc. 2014 Feb 28;3(1):e000660. doi: 10.1161/JAHA.113.000660.


Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.

Ekbom T, Linjer E, Hedner T, Lanke J, De Faire U, Wester PO, Dahlöf B, Scherstén B.

Blood Press. 2004;13(3):137-41.


Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M; ALLHAT Collaborative Research Group.

Hypertension. 2014 Nov;64(5):1012-21. doi: 10.1161/HYPERTENSIONAHA.114.03850. Epub 2014 Aug 4.


Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure.

Asayama K, Ohkubo T, Metoki H, Obara T, Inoue R, Kikuya M, Thijs L, Staessen JA, Imai Y; Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP).

Hypertens Res. 2012 Nov;35(11):1102-10. doi: 10.1038/hr.2012.125. Epub 2012 Aug 16.


Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension.

Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P, Zellig P.

J Am Coll Cardiol. 1998 Nov;32(5):1228-37.


The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).

Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT Jr, Whelton PK; SPRINT Study Research Group.

Clin Trials. 2014 Oct;11(5):532-46. doi: 10.1177/1740774514537404. Epub 2014 Jun 5.


Systolic blood pressure and cardiovascular outcomes during treatment of hypertension.

Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, Velazquez EJ, Pitt B, Jamerson K.

Am J Med. 2013 Jun;126(6):501-8. doi: 10.1016/j.amjmed.2013.01.007. Epub 2013 Mar 28.


Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).

Sever PS, Chang CL, Prescott MF, Gupta A, Poulter NR, Whitehouse A, Scanlon M.

Eur Heart J. 2012 Dec;33(23):2970-9. doi: 10.1093/eurheartj/ehs241. Epub 2012 Aug 31.


Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.

Circulation. 2006 May 9;113(18):2201-10. Epub 2006 May 1.


Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Barzilay JI, Jones CL, Davis BR, Basile JN, Goff DC Jr, Ciocon JO, Sweeney ME, Randall OS; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group.

Diabetes Care. 2001 Apr;24(4):654-8.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk